🚨 LIVE EVENT! ▶️
Register here: onc-rg.com/heme-outlook...
Join ONCrg analyst, Patrick Nygren, Ph.D., for a 15-minute spotlight on the Heme Outlook for 2025
Tuesday, December 2nd
⏰11:00 AM EST
Stay ahead of the curve with insights that matter.
#ASH2025 #ASH25 #clinicalresearch #ONCrg

🚨 SITC 2025
We’ll be watching closely as new analyses from HARMONi-A aim to clarify two key questions in EGFRm+ NSCLC:

Last year at SITC, discussants highlighted two areas they saw as the future of immunotherapy: vaccines and cell therapies. Fast forward to 2025, and the agenda reflects that very prediction. The ONCrg team will be onsite covering the latest data.
#ImmunoOncology #MarketInsights #ClinicalResearch

FDA approves pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection.
📒This approval sets pembrolizumab up to continue being competitive with nivolumab and atezolizumab, which also had SC formulations approved within the last year.
www.fda.gov/drugs/resour...

🚨 ONCrg #esmo25 Analyst Briefing: Breast Cancer
LIVE EVENT! 👉Register here: onc-rg.com/esmo-br-prev...
Join ONCrg analyst Carla Cabrera, Ph.D., for a 15-minute spotlight session on emerging breast cancer data, trends, and implications.
📅 Tuesday, October 7th
⏰ 11:00 AM EDT
#oncology #breastcancer

#ESMO2025 is coming up fast, and it’s a lot to process. That's why our analysts have done the heavy lifting. These pie charts summarize what we'll be analyzing. Request ONCrg's ESMO planner for more details: onc-rg.com/conferences/...

#ESMO25 #CancerResearch #Pharma #oncology

ONCrg is excited to attend Pharma CI USA, Sept 17–18 in NJ! If you’re attending, we’d love the opportunity to meet and share more about ONCrg’s offerings and how we support strategic decision-making.
#PharmaCI2025 #Biotech #CompetitiveIntelligence #CompetitiveStrategy #ONCrg

ONCrg will be providing in-depth coverage of NSCLC, SCLC, and immuno-oncology throughout the Plenary Sessions and other defining moments at #WCLC2025.

ONCrg's WCLC 2025 Details: onc-rg.com/conferences/...

#oncology #nsclc #sclc #thoraciccancer #pharmaCI #competitivestrategy #ONCrg

📢 New addition to our ADC landscape report!
As China's ADC landscape grows more crowded, identifying programs that are truly innovative is key.
Request sample for more details: onc-rg.com/pipeline-sam...
#oncology #ADCs #pharma #pharmainsights #pipeline #competitivestrategy